Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

This double-blind, randomized trial compared canagliflozin with placebo in patients with type 2 diabetes and evidence of kidney disease that was treated with renin–angiotensin system blockade. The canagliflozin group had a lower risk of kidney disease progression or cardiovascular events than the pl...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 380; no. 24; pp. 2295 - 2306
Main Authors: Perkovic, Vlado, Jardine, Meg J, Neal, Bruce, Bompoint, Severine, Heerspink, Hiddo J.L, Charytan, David M, Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Cannon, Christopher P, Capuano, George, Chu, Pei-Ling, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Wheeler, David C, Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Meininger, Gary, Brenner, Barry M, Mahaffey, Kenneth W
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 13.06.2019
Subjects:
Aged
Amputation
Angiotensin
Antidiabetics
Canagliflozin - adverse effects
Canagliflozin - therapeutic use
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Cerebral infarction
Clinical outcomes
Clinical trials
Collaboration
Creatinine
Creatinine - blood
Death
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Nephropathies - complications
Diabetic Nephropathies - drug therapy
Dialysis
Double-Blind Method
End-stage renal disease
Enzymes
Female
Follow-Up Studies
Glomerular Filtration Rate
Heart diseases
Hemodialysis
Humans
Immunosuppressive agents
Kidney diseases
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - prevention & control
Kidney transplantation
Laboratories
Male
Middle Aged
Myocardial infarction
Nephropathy
Renal failure
Renin
Sodium
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This double-blind, randomized trial compared canagliflozin with placebo in patients with type 2 diabetes and evidence of kidney disease that was treated with renin–angiotensin system blockade. The canagliflozin group had a lower risk of kidney disease progression or cardiovascular events than the placebo group.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1811744